The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance plans, a new survey shows.
Most U.S. employers don’t cover weight loss drugs — and fewer plan on doing so
Less than a fifth of large employers in the U.S. include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound, a KFF survey finds.
Only about 1/5 of large companies cover drugs for weight loss
A survey of employers finds that only about a fifth of large companies cover drugs like Wegovy for weight loss. A majority of companies that do cover the medicines have requirements.
Popular Weight Loss Drugs To Become More Expensive As Shortage Ends
With the shortage over, compounding pharmacies are no longer allowed to produce the popular weight loss drugs.
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
STAT3h
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
FiercePharma2d
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
Trade group sues FDA over ending Mounjaro/Zepbound shortage
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Axios on MSN7d
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...
JD Supra17h
Tirzepatide Shortage Resolved
On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...